Thank you for joining the Standard BioTools and Treeline Biosciences merger announcement conference call. I would now like to turn the call over to John Graziano, Standard BioTools Vice President of Investor Relations. Please go ahead. Thank you, operator. Joining me on today's call is Michael Egholm, Standard BioTools President and CEO, and Josh Bilenker, CEO and Co-Founder of Treeline. Before we begin, I would like to remind everyone that certain statements made on this call may be considered forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of assumptions, risks, and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risk factors are discussed in detail in our press release and investor presentation and other filings that we make with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except to the extent required by law. With this, I will turn it over to Michael. Thank you, John. I first want to walk through the process conducted by the management team and the Standard BioTools board of directors that led to this transaction, and why we believe this is the best path forward to maximize value for Standard BioTools shareholders. We'll then review the terms of the transaction, and Josh Bilenker, Treeline's Co-Founder and CEO, will provide an overview of Treeline, the company's differentiated approach to drug development, its clinical-stage pipeline, and the value creation opportunity ahead. Standard BioTools was founded with a thesis that thoughtful capital allocation, combined with disciplined execution and a lean operating model, can unlock shareholder value by accelerating breakthroughs in human health. Since inception, we have remained focused on those core principles, acquiring a portfolio of innovative tools that uncover unique insights and help accelerate drug discovery while improving our profitability profile. We have also taken a capital markets approach to our portfolio, for example, divesting SomaLogic to Illumina to unlock value and strengthen our balance sheet. When we completed the transaction with Illumina earlier this year, we embarked on an exhaustive review of strategic opportunities, evaluating assets of various sizes and profiles, ranging from smaller bolt-on acquisition to more transformative transactions and everything in between. We did not limit ourselves to just life science tools, but rather focused on a broad range of opportunities to maximize shareholder returns through a disciplined framework to identify attractive assets at the right valuation where we could create value. Out of this process, we came to the conclusion that deploying our capital in a merger with Treeline is the best path forward to maximize value for our shareholders. Treeline has assembled an exceptional team of proven drug developers and built a compelling portfolio of precision medicines spanning multiple therapeutic areas and modalities with the potential to address significant areas of unmet need. We believe the combination of financial strength, a pipeline with near and long-term catalysts, and the successful track record of this management team offers shareholders a compelling opportunity for value creation that exceeds what we believe we could achieve on our own. Let me walk you through the key terms of this transaction. This is an all-stock transaction whereby current Standard BioTools shareholders are expected to own approximately 16%, and current Treeline shareholders are expected to own approximately 84% of the combined company. The new company will operate as Treeline, and the current Treeline team will run the business with Josh and Jeff's continued leadership. Given our ownership position in the new company, two Standard directors will join the combined board. Treeline does not intend to operate our mass cytometry and microfluidics business units. As such, we're in the process of exploring a range of opportunities, including divestitures, to maximize the value of the two businesses. Our mass cytometry and microfluidics businesses are differentiated technologies that allow our customers to uncover unique insights into human health. We believe pursuing independent options for each business is the most effective path forward for our people, the technology, and our customers. Any incremental net proceeds received after the Treeline merger from our legacy assets, including the mass cytometry and microfluidics businesses, and up to $50 million in earn-out payments and royalties related to our completed SomaLogic transaction with Illumina, will be returned to pre-merger Standard BioTools stockholders through a contingent value right to be settled in a transition as part of the combined company. The Standard BioTools board of directors and a special committee of the Standard BioTools board of directors has approved this transaction. Finally, we have signed voting agreements with certain of our shareholders and expect to complete the transaction in the second half of 2026, once we have received all of the required approvals. With that, let me turn the call over to Josh to share more about Treeline. Josh? Good morning, everyone. I want to begin by taking a moment to thank Michael, the management team, and the board of directors of Standard BioTools for their support and belief in our team and our pipeline. I look forward to working for all of our collective shareholders and leading the combined company towards many exciting near and long-term goals. Our merger with Standard BioTools strengthens an already strong balance sheet as we enter 2027 and 2028. We believe these will be transformative years for Treeline, as you will hear in a moment when I talk about the pipeline. We expect pro forma combined cash at close to exceed $900 million, which will support interim data readouts for our clinical stage programs, as well as support several exciting new clinical trial starts. Let me start with some backstory. I'm a trained oncologist and have dedicated my career to bringing new medicines from scientific concept to FDA approval. In the past, I worked as an FDA reviewer and a venture capital investor. For the last 13 years, I've been a biotech founder and operating CEO. Before Treeline, I founded and led Loxo Oncology as CEO, guiding the company from inception to its sale to Eli Lilly in 2019. After the sale, I served briefly at Lilly as head of a newly formed oncology unit before starting Treeline. The thing I'm most proud of from that time is that all three Loxo programs became FDA-approved medicines. Five years ago, Jeff Engelman and I co-founded Treeline with the goal of creating an enduring biopharma company that could credibly and repeatedly discover drugs against high-value molecular targets in oncology and other serious diseases. Jeff was on the founding scientific advisory board of Loxo. He worked at NIBR Novartis running oncology R&D. Jeff's ability to identify new drug opportunities, recruit a superlative team, design experiments, and adapt to new data are just some of his unique talents. When we first launched Treeline, we asked investors for a long cash runway that wasn't contingent on interim milestones so that we could build a deep pipeline from scratch. We pitched a company discovery model built around multiple teams of internal domain experts who had a track record of delivering clinical candidates. We believed then, and even more so now, that drugging difficult targets requires hand-built solutions. Today, Treeline has sub-teams with proven expertise in small molecule inhibitors, protein degraders, and targeted therapy ADCs. This menu of technologies allows us to consider a wide berth of molecular targets. More about that later. Our platform story is repeatability. We want to be known as a company that picks good targets, nominates great development candidates, and makes thoughtful development decisions. We want to be a company that proves it can do those things over and over. We use some very cutting-edge methods in the lab and in silico to get things done, we don't speak about them loudly. We want to be defined by our clinical data, not our enabling tools. In just five years, we have generated an exciting pipeline of 10-plus homegrown programs. I'll talk through some of them now, and I encourage you to reference the accompanying slide deck for additional details. The first program I'll talk about is TLN-121, an oral protein degrader targeting BCL6. BCL6 is a lineage transcription factor that has long been a target of interest in lymphoma. Published data show that traditional inhibitors targeting BCL6 do not sufficiently suppress the target to cause tumor regression. Our team used the degrader approach and put forward a chemical series that had an unusual combination of potency, selectivity, and oral pharmacology. TLN-121 was designed to minimize the degradation of off-target proteins, which we believed should lead to improved tolerability in patients. Given the many active available therapy classes for lymphoma, combinability was an important design feature for 121. Combination regimens that include chemotherapy, CD19 and CD20 targeted therapies, CAR T, and other drug classes will likely be important to maximizing the potential of 121 or any new anti-lymphoma agent. We are currently enrolling a phase I trial for TLN-121 in patients with B-cell and T-cell lymphoma. 121 has shown compelling single-agent activity and a favorable safety profile in heavily pretreated patients. In our first 19 efficacy-evaluable patients, we have seen tumor regressions at all doses and across diffuse large B-cell lymphoma, follicular lymphoma, and T follicular helper cell subsets of peripheral T-cell lymphoma. The overall response rate is 84%, and the complete response rate is 32%, as measured by the Lugano criteria. In 2027, we plan to announce interim data and provide long-term development guidance about what we believe could be a practice-changing medicine in lymphoma. I'll turn now to TLN-254, an oral EZH2 inhibitor, which is also in development for lymphoma. EZH2 is a master regulator of cell proliferation, apoptosis, and senescence. We licensed ex-China rights to 254 from Jiangsu Hengrui Pharmaceuticals, which markets the agent in China in relapsed refractory peripheral T-cell lymphoma. We licensed 254 because we were intrigued by its combination potential with TLN-121, especially in diffuse large B-cell lymphoma. We have been evaluating the pharmacokinetics of 254 in a Western population by studying it as a monotherapy in a dose-randomized phase I trial in peripheral and cutaneous T-cell lymphoma. Across both doses, in 21 efficacy-evaluable peripheral T-cell lymphoma patients, we've observed an overall response rate of 62% with a complete response rate of 33%, as measured by the Lugano criteria. These data are substantially similar to those reported by Hengrui. On June 2nd, the FDA placed a partial clinical hold on the TLN-254 monotherapy phase I study and the TLN-254 combination cohorts within the TLN-121 phase I study due to concerns regarding the potential for secondary malignancies. This FDA action follows Ipsen's voluntary withdrawal of its EZH2 inhibitor, TAZVERIK, in response to an imbalance of secondary malignancies observed in its confirmatory phase III trial in follicular lymphoma. Enrollment in the TLN-254 monotherapy study and the combination cohorts of the TLN-121 study have been paused. Patients currently deriving clinical benefit from 254 may continue treatment, and investigators are in the process of re-consenting them and explaining the reason for the partial clinical hold. We are deeply committed to patient safety and are working with the agency to address the partial hold. We continue to believe, as do many of our investigators, that 254 may warrant further evaluation in combination with TLN-121 in aggressive lymphomas where unmet medical need remains high. Our third clinical program is TLN-372, an oral KRAS inhibitor. I trust most people listening to this are familiar with the KRAS landscape and some of the recent news out of ASCO. You may be asking yourself how Treeline fits into a world of pan-RAS inhibitors, mutant-selective inhibitors, and even other pan-KRAS inhibitors. We also didn't expect to answer such questions with interim clinical response and safety data in 2027. For now, we will outline some of the concepts that motivated us to design 372 from scratch and how its results may not correlate with those other pan-KRAS inhibitors. We expect 372 to differentiate in the clinic based on its ability to achieve therapeutic free drug exposures throughout the dosing period and to avoid HRAS and NRAS-mediated toxicities. This profile should allow for the deep-target inhibition required for single-agent responses, as well as for dose-intense combinability with cytotoxics, immunotherapies, anti-EGFR antibodies, and other drug classes. We believe strongly, because of the biology of RAS-mutated cancer, that dose-intense combination regimens are the future of the field, especially in earlier lines of therapy. We are enrolling a phase I dose-escalation trial for TLN-372 in patients with KRAS mutant or KRAS wild-type amplified solid tumors. Currently in our 4th dose level, we are solidly on thesis with PK observed to date in patients consistent with preclinical modeling. We believe 372 has the potential to avoid the drug exposure limitations that have been common in the KRAS inhibitor field. We are optimistic that we will be able to reach our pharmacokinetic objectives and that selectivity against HRAS and NRAS will avoid some of the toxicities that have limited dose intensity for other programs. I'll turn now to a fourth program, TLN-499, which is expected to enter the clinic this year. 499 is an oral protein degrader that selectively targets BCL-XL. Certain cancer cells rely on BCL-XL alongside other pro-survival proteins to prevent apoptosis. Extensive literature suggests that antagonizing BCL-XL could meaningfully potentiate other drug classes, such as chemotherapeutics and targeted therapies, including EGFR, KRAS, BRAF, MEK, and BCL2 inhibitors. To figure out which, if any, of these combination pairs had the potential for the best clinical results, we relied on data from over 200 patient-derived xenograft models to prioritize our development plans. Another thing we had to figure out for this program was how to manage platelet toxicity, since BCL-XL is an essential mediator of platelet survival. 499 was designed to potently degrade BCL-XL, which may mitigate but not eliminate the platelet toxicity observed with previous generations of inhibitors. Despite the development complexities, internal data for 499 are compelling and we believe support a clear clinical path. We are eager to get started in the clinic soon. To review, our first three homegrown clinical programs, 121, 372, and 499, are a degrader, an inhibitor, and a degrader, respectively. All three targets, BCL6, KRAS, and BCL-XL, are oncology targets. The next three expected clinical entries involve some Treeline themes that I haven't mentioned yet. One is our interest in therapeutic areas outside of oncology. Another is the platform build we undertook to be able to address previously unliganded pockets and proteins. A third is our excitement around targeted therapy ADCs. The next three expected clinical entries include programs that address diseases outside of oncology, more specifically neurology and immunology. As noted at the beginning of my remarks, we see ourselves as target pickers who make good drug design and development choices. Many of our team members have worked in other therapeutic areas, and we often consider new program concepts that we think can work, make a difference for patients, and play to the strengths of our team. A previously unliganded target refers to a protein domain for which there is nothing in the public sphere, be it the peer-reviewed literature or the patent literature, showing that a small molecule can bind to it. Put another way, it is a target that has no known starting points for a medicinal chemist. Addressing previously unliganded pockets and proteins requires team and technology capabilities that include real and virtual compound libraries, protein science, novel biochemistry and biophysical assay development, structural biology, i n vivo model development, and extensive computational enablement. The last part, computation, includes physics-based modeling, AI, and workflow solutions that connect different data sources. We have learned that the true power of computation comes only through tight integration with traditional wet lab teams. After a lot of work and fine-tuning, I'm pleased that we have teams, technologies, and processes that are putting up results against previously unliganded pockets and proteins. We expect at least one near-term clinical entry from this category. Last, a word on targeted therapy ADCs. These are ADCs that use a precision medicine payload instead of a cytotoxic. The antibody's job is to direct the payload away from a susceptible healthy tissue that otherwise would be responsible for a dose-limiting toxicity. Building a targeted therapy ADC requires antibody and linker expertise, as well as the ability to pursue difficult small molecule chemistry on the payload side. We expect at least one targeted therapy ADC to be among our next three clinical entries. Let me conclude with a brief comment on our data disclosure philosophy. As we move our clinical programs forward and as new programs enter the clinic, we want to ensure that we avoid incremental and confusing updates. Right now, we are guiding to clinical entry of TLN-499 in 2026, interim data readouts for TLN-121 and TLN-372 in 2027, and three additional clinical entries in 2027 and 2028. In the first quarter of 2027, we will provide additional program-level guidance. I want to close with a message of gratitude. Thank you to my fellow Treeline employees for taking a chance on each other and working so hard. Thank you to Treeline investors who have shared the vision and wanted to think big. Thank you to the team and investors at Standard BioTools for joining us on the journey. We promise to work hard for you. This concludes my remarks, and I will now hand the call back to the operator. This concludes our call. Thank you.